Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 104

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 104
---
 in the condensed consolidated statements of operations.

As
of June 30, 2025, the unamortized stock option expense was $549,822. As of June 30, 2025, the weighted average period for the
unamortized stock compensation to be recognized is 0.62 years.

Warrants

The
following is an analysis of the stock warrant grant activity:

    Weighted
    Average

    Weighted
    Average

    Number
    of
    Shares

    Exercise
        
        Price

    Remaining
    Life

    Stock Warrants

    Outstanding December 31, 2024

    5,500

    $
    75.00

    4.13

    Granted

    —

    —

    —

    Expired

    —

    —

    —

    Exercised

    —

    —

    —

    Outstanding June
    30, 2025

    5,500

    $
    75.00

    3.63

    Exercisable June
    30, 2025

    5,500

    $
    75.00

    3.63

    Weighted
    Average

    Weighted
    Average

    Number

    Exercise
        
        Price

    Remaining
    Life

    Stock Warrants

    Outstanding December 31, 2023

    —

    $
    —

    —

    Granted

    5,500

    75.00

    4.88

    Expired

    —

    —

    —

    Exercised

    —

    —

    —

    Outstanding June
    30, 2024

    5,500

    $
    75.00

    4.46

    Exercisable June
    30, 2024

    5,500

    $
    75.00

    4.46

    19 

A
summary of the status of the Company’s nonvested warrants as of June 30, 2025 and 2024, and changes during the three and
six months ended June 30, 2025 and 2024, is presented below:

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2024